bullish
SSI Weekly Newsletter Highlights: SWTX and NATH Potential Buyouts, LQDA FDA Update and More
658 Views03 Mar 2025 01:52
SpringWorks Therapeutics (SWTX) is in late-stage acquisition talks with Merck KGaA, with a potential buyout offer at $85/share.
What is covered in the Full Insight:
- Introduction to SSI Weekly Newsletter
- New Pitches: SWTX and NATH
- Portfolio Idea Updates: LQDA and BOOM
- Quick Pitch Updates: PAC, LOGC, ASLI, DXLG, and DK
- Conclusion and Market Trends
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Top Quartile
Special Situation Investments
Event-Driven Investment Opportunities
Price Chart(Sign Up to Access)
- SSI Weekly Newsletter Highlights: SWTX and NATH Potential Buyouts, LQDA FDA Update and More03 Mar 2025
x